Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 710 N Tucker Blvd, Ste 110 ST. LOUIS MO 63101 |
Tel: | N/A |
Website: | https://www.stereotaxis.com |
IR: | See website |
Key People | ||
David Leo Fischel Chairman of the Board, Chief Executive Officer | Kimberly R. Peery Chief Financial Officer |
Business Overview |
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company's primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. |
Financial Overview |
For the fiscal year ended 31 December 2023, Stereotaxis Inc revenues decreased 5% to $26.8M. Net loss applicable to common stockholders increased 12% to $22.1M. Revenues reflect United States segment decrease of 8% to $18.2M. Higher net loss reflects Manufactures and markets robotic magnetic navigation systems segment loss increase of 16% to $21.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.26 to -$0.27. |
Employees: | 122 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $191.90M as of Dec 31, 2023 |
Annual revenue (TTM): | $26.77M as of Dec 31, 2023 |
EBITDA (TTM): | -$21.24M as of Dec 31, 2023 |
Net annual income (TTM): | -$22.06M as of Dec 31, 2023 |
Free cash flow (TTM): | -$9.51M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 82,128,762 as of Feb 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |